Not sure if this has been raised before, but just thought it was worth mentioning that MSB may receive a rare pediatric disease voucher for its GVHD trials.
For those who are not sure what a voucher is, our friends at wiki can help:
Priority review voucher
This has significant ramifications for other programs that MSB have in play, and can significantly accelerate the approval process of another trial program run by MSB or possibly sold (as the voucher is transferable).
If a voucher is received - who benefits from it? Will it be used to expedite a current program run by MSB, or sold & proceeds split between MSB and Celgene? Yet another element that I am sure MSB and Celgene are discussing ...
I heard a recent voucher was sold for approx. $300m USD.
GVHD - a neglected disease
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.8¢ |
Change
-0.033(3.28%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $3.332M | 3.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 318994 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 106202 | 9 |
View Market Depth
| Last trade - 11.51am 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |